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largely unknown.
Methods: In the present study, the impact of these rare coding variants (in ABI3, PLCG2, and
TREM2) on all subcortical volumes is determined in a large sample of young healthy individuals
(N 5 756–765; aged 22–35 years).
Results: After multiple testing correction (PCORRECTED , .05), rare variants were associated with
basal ganglia volumes (TREM2 and PLCG2 effects within the putamen and pallidum, respectively).
Nominal associations between TREM2 and reduced hippocampal and thalamic volumes were also
observed.
Discussion: Our observations suggest that rare variants in microglia-mediated immunity pathway
may contribute to the subcortical alterations observed in AD cases. These observations provide
further evidence that genetic risk for AD may influence the volume of subcortical volumes and in-
crease AD risk in early life processes.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Magnetic resonance imaging; Freesurfer; Alzheimer’s disease; Microglia; Exome-sequencing; TREM21. Background
A recent exome sequencing study has revealed that risk
for Alzheimer’s disease (AD) is partly explained by rare (mi-
nor allele frequency,1%) single nucleotide variants within
ABI3, PLCG2, and TREM2, genes with known roles in
microglia-mediated innate immunity [1]. These variations
confer amino acid substitutions, which are likely to influence
protein function and or/expression. However, the neurobio-
logical mechanisms by which these variants confer suscepti-
bility are relatively unknown.
Preclinical studies suggest that AD is preceded by a pro-
gressive pattern of cortical/subcortical atrophy, where the: The authors have declared that no conflict of interest
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ns.org/licenses/by/4.0/).earliest evidence of histopathologic changes occurs in the
medial temporal lobe [2]. These alterations have been
explored via magnetic resonance imaging and broadly sug-
gest that AD risk variants may contribute to the progressive
atrophy that manifests in preclinical markers such the vol-
ume (cubic millimeters) of subcortical structures such as
the hippocampus and amygdala. Briefly, early work impli-
cated the strongest known common genetic risk factor for
AD (APOE locus) with alterations in the volume of these
structures, in early and later life processes [3]. More recent
work has adopted a multivariate approach to cumulatively
assess the impact of all common genome-wide association
studies–identified AD risk alleles [4] (as assessed via a poly-
genic risk scores) on brain structures such as the hippocam-
pus, suggesting that the combined influence of common risk
alleles for AD may confer risk in early life process [3,5–10].
Together, these neuroimaging genetic studies provide insight
into the mechanisms by which common risk alleles for ADeimer’s Association. This is an open access article under the CC BY license
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the medial temporal lobe volumetry, making them more
vulnerable to atrophy in later life.
However, little is known about rare coding variants’ influ-
ence on the AD-susceptible regions of the brain. The prelim-
inary evidence suggests that comparable to the combined
effects of common AD risk alleles, rare AD variants within
TREM2 are also associated with reduced hippocampal vol-
ume, in older individuals [7,11]. Together, these studies
suggest that both common and rare risk alleles for AD
may confer susceptibility by common pathways. However,
the impact of recently identified variants within ABI3 and
PLCG2 on neuroimaging markers such as subcortical
volume has not been assessed. On the basis of the
common biological function by which these locus operate
(microglia-mediated innate immunity), it is anticipated
that these rare risk alleles will also contribute to the
volumetric alterations that precede AD symptomology.
In the present study, the subcortical volumes of carriers of
minor alleles within ABI3, PLCG2, and TREM2 with non-
carriers are compared, in a large population of young,
healthy individuals. The impact of these risk alleles is
explored in a young cohort to minimize the confounding
impact of orthogonal, interactive environmental AD risk fac-
tors that also influence subcortical brain volumes such as age
and lifestyle factors [12–14]. On the basis of the prior
evidence suggesting that subcortical volume alterations
may be a common mechanism by which common and rare
AD risk allele may confer susceptibility [7], it is anticipated
that the individuals that possess the risk alleles at these loci
will have alterations in subcortical volumetry, specifically
within the medial temporal lobe (hippocampus, amygdala).2. Materials and methods
2.1. Participants
Data were drawn from the publicly available repository of
the WU-Minn Young Adult Human Connectome Project;
(http://www.humanconnectome.org/). The scanning protocolTable 1
Demographic details for the final sample, stratified by ABI3, PLCG2, and TREM2
N 5 766
ABI3: rs616338 (minor allele 5 A) PLCG2: rs72
GG
N 5 748
AG
N 5 18
CC
N 5 743
Age 29.024 3.590 29.167 3.714 29.046
Gender (F/M) 394/354 10/8 394/349
Handedness 68.242 41.390 66.944 34.816 68.082 4
APOE 34 (2/1) 568/180 12/6 561/182
Body mass index 26.229 4.928 28.910 5.374 26.298
Education 15.082 1.699 14.722 1.873 15.078
Employment 1.588 0.695 1.444 0.784 1.585
NOTE. Mean6 standard deviation. APOE 34 (2/1) represent individuals who
via the Edinburgh handedness scale. Education and employment were assessed via
the Young Adult Human Connectome Project data dictionary: https://wiki.hum
Updated1for1the112001Subject1Release.was approved by theWashington University in the St. Louis’s
Human Research Protection Office, Institional Review Board
no. 201204036. No experimental activity with any involve-
ment of human subjects took place at the author’s institutions.
Participants were drawn from the March 2017 public data
release from the Human Connectome Project, a cross-
sectional, multimodal genetic-neuroimaging cohort of young
adults (N 5 1206). All participants were aged from 22 to 35
years, for all inclusion/exclusion criteria, see Van Essen et al.
[15]. Briefly, the study excluded individuals with a personal
history of psychiatric disorder, substance abuse, neurologic
or cardiovascular disease, and associated hospitalization or
long-term (.12 months) pharmacologic/behavioral treat-
ment. For a full brief of inclusion/exclusion criteria, please
see Supplemental Table 1 ofVan Essen et al. [15]. Participants
were excluded from the current analyses if they lacked good-
quality structural magnetic resonance imaging data, or had
missing relevant genetic, interview/questionnaire data.
Further information about the HCP kinship structure is
available at http://www.humanconnectome.org/storage/app/
media/documentation/s1200/HCP_S1200_Release_Reference_
Manual.pdf. To control for population bias, the sample was
further restricted to individuals of Caucasian descent. Each
of the three variant groupings (ABI3, PLCG2, and TREM2)
were equally represented across gender and APOE 34 status
(c2 test, P. .1, in all cases) and did not differ in age, handed-
ness, body mass index, education, and employment (indepen-
dent sample t test, P . .1, in all cases). See Table 1 for
complete description of the demographic data.2.2. Genotyping
All Young Adult Human Connectome Project data are
publicly available, including genome-wide genotype data
to be distributed through the database of genotypes and phe-
notypes. From this data set, 1141 subjects were genotyped,
and 1,580,642 single-nucleotide polymorphism (SNPs)
passed initial quality control. Quality control was imple-
mented in PLINK v1.9 [16]. Briefly, SNPs were excludedgenotypes
824905 (minor allele 5 G) TREM2: rs143332484 (minor allele 5 T)
GC
N 5 23
CC
N 5 752
TC
N 5 14
3.588 28.435 3.691 29.013 3.594 29.786 3.468
10/13 394/358 10/5
1.345 72.391 37.865 68.351 41.034 60.714 51.882
19/4 571/181 9/5
4.980 26.113 4.039 26.287 4.963 26.553 4.500
1.700 14.913 1.832 15.072 1.704 15.143 1.703
0.697 1.565 0.728 1.584 0.697 1.643 0.745
possessed at least one copy of the APOE 34 allele. Handedness was assessed
SSAGA_Education and SSAGA_Employment, respectively, as described in
anconnectome.org/display/PublicData/HCP1Data1Dictionary1Public-1
Table 2
Standardized beta estimate of each variant on the seven subcortical volumes.
Effect estimate reflects the impact of the minor allele at each of the three
variants
Variant Volume (mm3) Standard b Std. Error P
ABI3_rs616338 Accumbens area 20.06729 0.215404 .754754
Amygdala 0.059058 0.193288 .759951
Caudate 0.114756 0.215069 .593634
Hippo 0.121099 0.209561 .563353
Pallidum 0.134907 0.21283 .526165
Putamen 0.214194 0.210183 .308164
Thalamus proper 0.127384 0.188806 .499878
PLCG2_rs72824905 Accumbens area 20.23319 0.195503 .23296
Amygdala 20.24926 0.171324 .145704
Caudate 20.18399 0.198696 .354459
Hippo 20.12729 0.186125 .494059
Pallidum 20.52205 0.192925 .00681
Putamen 20.42581 0.190697 .025554
Thalamus proper 20.20704 0.171346 .226934
TREM2_rs143332484 Accumbens area 20.2366 0.267889 .377128
Amygdala 20.28245 0.235478 .23034
Caudate 0.019829 0.273673 .942241
Hippo 20.56729 0.255265 .02626
Pallidum 20.23682 0.276474 .391683
Putamen 20.76972 0.265246 .003709
Thalamus proper 20.47425 0.233696 .042423
NOTE. Bold represents significant associations after multiple testing
correction.
Abbreviations: b5 Standardized beta estimate; Std. Error5 standard er-
ror of effect estimate.
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Hardy-Weinberg equilibrium had a P value less than
1 ! 1024. Individuals were excluded for ambiguous sex
(genotypic sex and phenotypic sex) not aligning or genotyp-
ing completeness less than 97%. The candidate variants
within ABI3 (rs616338), PLCG2 (rs72824905), and
TREM2 (rs143332484) passed quality control. No individual
in the sample possessed two copies of the minor allele at any
of the three loci. Variation in the sample kinship structure
was further controlled in all analysis (see Section 2.4). Indi-
vidual APOE status was also determined by the absence/
presence of a 34 allele (rs7412; rs429358).
2.3. Data acquisition, preprocessing, and quality control
Human Connectome Project sample: Images were ac-
quired using a customized Siemens Skyra 3-T scanner
with a 32-channel head coil. For details on data acquisition
and preprocessing, see Glasser et al. [17]. Subcortical and
intracranial volumes (cubic millimeters) were estimated
with Freesurfer v5.2 [18], which were subsequently used
for the Young Adult Human Connectome Project minimal
processing pipeline [17]. Seven subcortical volumes (ac-
cumbens, amygdala, caudate, globus pallidus, hippocampus,
putamen, and thalamus) were averaged across hemisphere
and adjusted for intracranial volume, a method previously
established by recent genomic studies part of the Enhancing
Neuro Imaging Genetics through Meta-Analysis consortium
[19,20]. After all complete data (N 5 766) were considered
and the statistical outliers for each subcortical volume were
determined, the final sample size range was N 5 756–765).
2.4. Statistical inferences
Linear mixed-effects (LME) models were estimated in R
(https://www.r-project.org/) using the ‘lmer’ package, as a
previously recommended solution for regression models
with latent familial correlation structure [21]. Briefly, each
of the seven corrected subcortical volumes was entered into
mixed-effects models with ABI3, PLCG2, and TREM2 as
fixed effects, age, sex, APOE status (absence/presence of an
APOE 34 allele), handedness, body mass index, education,
and employment covariates of no interest. To account for
the familial structure in the sample, a sparse kinship matrix
was included in each of the seven LME models using the
“lme4qt” extension package [22] (see Equation 1). Subcor-
tical volumes that were statistical outliers were removed using
the interquartile rangeoutlier labeling rule (1.5! interquartile
range (Q3–Q1)) as previously described [23]. P values were
adjusted by corrected for the number of LME models
(PCORRECTED 5 .05/7). To further establish potential
confounding from the kinship structure, we split the sample
into “twin” and “nontwin” samples and re-estimated the
effects using the “metafor” package [24].
g5 Xb1 Zy1 ε (1)Equation 1 is taken from [22]. When n equals the sample
size, X[n! p] and Z[n! n] are incidence matrices and p is
the number of fixed effects (SNPs and covariates). b[p! 1]
is a vector of fixed effects, n ! 1 is a vector of a random
polygenic effect, and ε[n! 1] reflects the residual error.3. Results
There were no associations (corrected/uncorrected)
between ABI3 variant and subcortical structures. After
controlling for the multiple testing, the minor allele at
the PLCG2 locus was associated with reduced volume
(cubic millimeters) in the pallidum (PCORRECTED 5 .035)
and the TREM2 locus and volume in the putamen
(PCORRECTED 5 .028). We observed nominal associations
between (1) PLCG2 and the putamen
(PUNCORRECTED 5 .026) and (2) between TREM2 and the
hippocampus (PUNCORRECTED 5 .026) and thalamus
(PUNCORRECTED 5 .042). See Table 2 and Fig. 1 for all
estimated effect sizes and 95% confidence intervals.
To further control for variation in the kinship structure,
we then proceeded to split the sample into twins and nontwin
groups. The pooled effects remained largely unchanged:
PLCG2-pallidum, P 5 .01; PLCG2-putamen, P 5 .009;
TREM2-hippocampus, P 5 .011; and TREM2-putamen,
P 5 .039. See Fig. 2 for estimated effects and 95% confi-
dence intervals.
Fig. 1. X-axis5 corrected volumes (adjusted for all covariates) across seven subcortical volumes (Y-axis) for the three variants. Abbreviations: Black5minor
allele; gray 5 major allele. Error bars represent 95% confidence intervals.
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The association between three rare microglia-linked AD
risk alleles on subcortical volumes was assessed in a large
sample of young individuals. Consistent prior reports [7,11],
the rare AD-associated variation within TREM2 was
nominally associated with reduced hippocampal volume.
Here, these prior observations are expanded on to show that
these alterations are also present in early life process. Together,
accumulating evidence now suggests that both common and
rare variations that confer risk for AD may converge on
pathophysiological mechanisms such as alterations in
subcortical volumetry in early life [6,8]. Furthermore, there
was a negative association between the TREM2 risk allele
and volume of putamen. This adds to evidence from
previous studies have also shown that common AD risk loci
such as BIN1 and ABCA7 are also associated with
alterations in putamen volumes [25]. We further observedFig. 2. X-axis 5 Standardized beta coefficient (adjusted for all covariates) acros
Black (circle) 5 twin sample; gray (circle) 5 nontwin sample. Black (diamond)negative associations between the PLCG2 protective locus
and pallidum/putamen volumes. The observations between
PLCG2/TREM2 and basal ganglia volume provide novel
insight into mechanisms by which microglia-mediated innate
immunity may confer risk for AD. It is of interest that the
minor allele at PLCG2 (protective allele) and TREM2 (risk
allele) were both associated with a reduction in putamen
volume. This suggests that although putamen volume may
be a common mechanism by which rare AD genetic risk is
conferred, the precise molecular mechanisms that lead to
opposing phenotypes should be explored. The ABI3,
PLCG2, and TREM2 transcripts have a common expression
pattern in human brain cortex, with high expression in micro-
glia cells and limited expression in neurons, oligodendrocytes,
astrocytes, and endothelial cells, suggesting that future imag-
ing genetic studies of AD-related risk would benefit from
imaging measures sensitive to microglia function [26–28].s seven subcortical volumes (Y-axis) for the three variants. Abbreviations:
5 pooled estimate. Error bars represent 95% confidence intervals.
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leles may also confer susceptibility via alterations in subcor-
tical volumes, specifically in the medial temporal lobe and
basal ganglia. The AD-associated risk loci within PLGC2
and TREM2 confer protein changes, these variants may in-
fluence subcortical volumetry via alteration in protein func-
tion and/or expression, which have yet to be elucidated. Our
observation is also supported by recent histologic evidence
showing that AD genetic risk (with and without APOE) is
associated microglia density exclusively within temporal
lobe structures [29]. Innate immunity represents a significant
component in the broad genetic architecture of AD [29];
however, the relationship between neuroimaging markers
of AD risk and immune function remains limited. Initial im-
aging studies have shown that marker of inflammation such
as C-reactive protein are associated with cortical volume
loss [30,31].
Our observations should be interpreted with several con-
siderations. First, as these three variants considered in this
analysis are uncommon (minor allele frequency ,1%),
these sample sizes for the respective minor alleles were
small (NRANGE: 14–23). However, as our observations are
consistent with prior associations [7,11,32], we suggest
that this work may add important insight into rare AD
variants across the lifespan. Second, as the effects of these
variants were assessed in a cross-sectional sample, it is un-
known how variants affect brain structure across the life-
span. Furthermore, large imaging consortia projects such
the lifespan development and aging projects will be instru-
mental in assessing the impact of common and rare AD
risk alleles in early and later-life processes [33]. Finally, it
is of note that the rare variants were largely contained within
families. Our (A) mixed-effects models and (B) split-half
analysis provide support in the findings, providing further
evidence for associations between hippocampal volume
and TREM2 [7,11]. There is also evidence that rare
variation in TREM2 may also influence basal ganglia
volumes [32] and altered markers of brain health (such as ce-
rebral blood flow/ventricular expansion) in animal models
[34,35]. However, observations between PLCG2 and
putamen volume should be interpreted with caution until
replicated in independent samples. Nevertheless, the
associations between the PLCG2 and TREM2 loci and
putamen/globus pallidus broadly suggest that the
volumetric reductions in basal ganglia may reflect a
immunogenic mechanism of AD-linked susceptibility that
manifests in early life process and a potential target for
detection, prevention, and intervention.5. Conclusion
This study demonstrates associations between subcortical
volumes (basal ganglia) and rare AD genetic risk in locus
with known functions in microglia-mediated innate immu-
nity (PLCG2 and TREM2). These observations contribute
to a growing body of evidence suggesting that genetic vari-ation (rare and common) may contribute to AD risk in early
life by influencing the volume of subcortical structures.
Future bioinformatics research will help to refine and un-
cover the principle biological gradients (such as microglia-
mediated innate immunity) that underpin AD genetic risk
and neuroimaging correlates [36]. Future in vivo neuroimag-
ing measures that map immunity/microglia function in the
brain will elucidate unknown mechanisms of AD risk and
aid in the understanding of the pathophysiology preceding
clinical symptomology.Acknowledgments
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1. Systematic review: Recent exome sequencing
studies have identified rare variants in AIB3,
PLCG2, and TREM2 that influence risk for Alz-
heimer’s disease (AD). However, the mechanisms
by which these loci confer risk are largely unknown.
This study explores the relationship between these
risk variants and brain volumes (via magnetic reso-
nance imaging) in early life process.
2. Interpretation: TREM2 risk was associated with
smaller putamen volumes. The PLCG2 variant was
further associated with reduced pallidum volume.
These variants may influence subcortical volumetry
at an early age, which may confer risk for AD in later
life.
3. Future directions: Microglia–mediated innate im-
munity may be a key component of AD genetic risk
that influences brain health. Future neuroimaging
studies that map immunity/microglia function in the
brain will elucidate unknownmechanisms of AD risk
and aid in the understanding of the pathophysiology
preceding clinical symptomology.
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